2020 Pediatric Grand Rounds | Thrombotic Microangiopathy (TMA): Repurposing Old Biomarkers for Novel Concepts
There is a lack of awareness of Thrombotic Microangiopathy (TMA) and lack of uniform guidelines to identify high risk patients with TMA who will benefit from prompt intervention.
Thrombotic Microangiopathy (TMA) is now recognized as a severe stem cell transplant complication, by recently published prospective studies in children. There are no prospective studies performed in adults so far. New disease biomarkers and new targetable targeted therapies had recently identified that significant improved TMA outcomes in children and are used in selected centers that focus on TMA research. This educational activity summarizes clinical and research study data that will aid in TMA management that can be implemented in clinical practiced at City of Hope with the goal to improve transplant outcomes.
Pediatric hematology/oncology physicians, advance practice practitioners, staff and research.
- Examine biomarker data that is being integrated into clinical studies and practice.
- Outline collaborative multidisciplinary research in proposing Thrombotic Microangiopathy (TMA) clinical guidelines.
- Review data from prospective multi-institutional studies.
- Outline the various types of cultural diversities (gender, age, race, religion, culture, etc.) that relate to demographics, diagnosis and treatment.
Virtual Meeting- Zoom
Sonata Jodele, MD Professor, Bone Marrow Transplantation and Immune Deficiency; Cincinnati Children's Hospital Medical Center
Dr. Jodele has indicated that she does not have anything to disclose.
Dr. Jodele will be discussing the off-label or investigational use of Eculizumab in Hematopoietic Stem Cell Transplantation population.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2020 Pediatric Grand Rounds | Thrombotic Microangiopathy (TMA): Repurposing Old Biomarkers for Novel Concepts for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance